Amgen Wins Sjögren's Trial as Novartis Lands Big Radioligand Deal
Amgen has announced success in its Phase 3 trial for Sjögren's syndrome, a chronic autoimmune disorder. This marks a significant milestone for the company.
The $900 million radioligand deal between Novartis and another unnamed entity is also noteworthy. Details of this agreement are scarce, but it highlights the growing interest in radioligands as a treatment approach.